Leerink Comments On Orexigen Therapeutics, Says Current Projections Could Prove To Be 'Conservative'

By: via Benzinga
In a report published Wednesday, Leerink analyst Paul Matteis commented on Orexigen Therapeutics, Inc. (NASDAQ: OREX) and wrote that ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.